Studies samples from people with bowel cancer that has spread to the liver
Studies samples from adults with bowel cancer in the liver receiving radiation treatment.
Plain-language title generated from the registry record
Registry title: Selective Internal Radiation Therapy With 90Y Resin Micropheres for Refractory Colorectal Cancer Liver Metastases
Key facts
- Where
- Aarhus N, DenmarkSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose colorectal cancer has spread mainly to the liver and cannot be removed or treated locally. Standard chemotherapy must have stopped working or caused severe side effects.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Metastatic colorectal adenocarcinoma with mainly liver disease. The liver metastases cannot be treated with resection, RFA or SBRT. The disease has progressed, or there was severe intolerance, during or after all standard chemotherapy lines. ECOG performance status 0-1.
- Earlier treatment
- Must be off all chemotherapy for 14 days and off vascular endothelial growth factor inhibitors for 6 weeks before SIRT. Must have had all standard lines of chemotherapy.
Main reasons for not taking part
- Pregnancy
- Lung shunt greater than 20% or more than 30 Gray radiation dose to the lungs on the Tc-99m-MAA scan
- Tc-99m-MAA deposition outside the liver in the stomach, duodenum or GI tract
- Ascites, or tumour volume greater than 50% of liver volume
- Active uncontrolled infection
Read by machine on 9 November 2026.
Where in Denmark
- Department of Oncology, Aarhus University HospitalAarhus N, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Aarhus University Hospital
- Trial code
- NCT04491929
- Record updated
- 13 January 2026
- Original description
Observational, feasibility study investigating biological aspects in patients with liver metastasis from colorectal cancer undergoing treatment with SIRT, by translational analysis of biological samples.Read full original descriptionShow less
Selective Internal Radiation Therapy With 90Y Resin Micropheres for Refractory Colorectal Cancer Liver Metastases - SIRT - A Translational Feasibility Study
Observational, feasibility study investigating biological aspects in patients with liver metastasis from colorectal cancer undergoing treatment with SIRT, by translational analysis of biological samples.
Inclusion: Diagnosis of metastatic colorectal adenocarcinoma with liver dominant disease; Diagnosis of liver metastasis may be made by histo- or cyto-pathology, or by clinical and imaging criteria; The Liver metastasis are not eligible for resection, RFA or SBRT; All patients must be off all chemotherapeutic regimens for 14 days prior to SIRT treatment; All patients must be off vascular endothelial growth factor inhibitors for 6 weeks prior to SIRT treatment; Progressive disease, severe intolerance during or following all standard lines of chemo-therapy; Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; Age 18 years or older; Able to understand written information; Consent to samples for translational research.
Exclusion: Previous radiation therapy to the lungs and/or to the upper abdomen overlapping with dose to the liver at interventionist´s decision; Lung shunt greater than 20% or > 30 Gray radiation absorbed dose to the lungs, at estimated by Tc-99m-MAA; Current or previously evidence of ascites on CT-scan or physical examination; Symptomatic lung disease precluding SIRT at interventionist´s decision; Active uncontrolled infection; Conditions precluding translational samples; Pretherapeutic work-up procedure with Tc-99m macroaggregated albumin (MAA) scintigraphy showing extrahepatic foci in GI-tract; Evidence of any detectable Tc-99m macroaggregated albumin deposition in the stomach or duodenum, after application of established angiographic techniques to stop such deposition; Any pre-treatment laboratory findings within 30 days of treatment demonstrating: alanine aminotransferase level greater than 5 times upper normal limit and/or serum bilirubin greater than 2 mg/dl (>34 umol/l); Pregnancy; Tumour volume greater than 50% of liver volume.